|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
40,450,000 |
Market
Cap: |
989.00(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$14.37 - $27.55 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Kiniksa Pharmaceuticals is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with unmet medical need. Co.'s portfolio of assets include: ARCALYST® (rilonacept) is for the treatment of Cryopyrin-Associated Periodic Syndrome; mavrilimumab is targeting granulocyte-macrophage colony stimulating factor receptor alpha; vixarelimab is evaluating vixarelimab for the potential treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404 is a humanized monoclonal antibody that is designed to inhibit the CD40-CD154 interaction.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
329,070 |
329,070 |
523,966 |
603,682 |
Total Sell Value |
$8,517,127 |
$8,517,127 |
$12,486,163 |
$13,833,432 |
Total People Sold |
5 |
5 |
6 |
7 |
Total Sell Transactions |
6 |
6 |
18 |
22 |
End Date |
2024-06-27 |
2024-03-26 |
2023-09-26 |
2022-09-26 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Megna Michael R |
Chief Accounting Officer |
|
2022-03-16 |
4 |
D |
$10.13 |
$2,725 |
D/D |
(269) |
3,930 |
|
- |
|
Megna Michael R |
Chief Accounting Officer |
|
2022-03-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
775 |
4,199 |
|
- |
|
Moat Ross |
Chief Commercial Officer |
|
2022-01-15 |
4 |
A |
$9.63 |
$14,888 |
D/D |
1,546 |
5,891 |
|
- |
|
Tessari Eben |
Chief Operating Officer |
|
2022-01-15 |
4 |
A |
$9.63 |
$9,341 |
D/D |
970 |
107,780 |
|
- |
|
Megna Michael R |
Chief Accounting Officer |
|
2022-01-15 |
4 |
A |
$9.63 |
$6,288 |
D/D |
653 |
3,424 |
|
- |
|
Moat Ross |
Chief Commercial Officer |
|
2021-07-15 |
4 |
A |
$11.49 |
$11,065 |
D/D |
963 |
4,345 |
|
- |
|
Tessari Eben |
Chief Operating Officer |
|
2021-07-15 |
4 |
A |
$11.49 |
$9,973 |
D/D |
868 |
106,810 |
|
- |
|
Megna Michael R |
Chief Accounting Officer |
|
2021-07-15 |
4 |
A |
$11.49 |
$6,756 |
D/D |
588 |
2,771 |
|
- |
|
Tessari Eben |
Chief Business OfficerOfficer |
|
2021-06-10 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
105,942 |
|
- |
|
Pano Arian |
Chief Clinical Dev. OfficerOff |
|
2021-06-10 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
1,539 |
|
- |
|
Moat Ross |
Group VP & Rilonacept GMOffice |
|
2021-04-09 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
3,382 |
|
- |
|
Patel Sanj K |
Chairman & CEO |
|
2021-02-10 |
4 |
AS |
$23.07 |
$26,231 |
I/I |
(1,137) |
83,336 |
|
- |
|
Patel Sanj K |
Chairman & CEO |
|
2021-02-10 |
4 |
AS |
$23.06 |
$36,896 |
D/D |
(1,600) |
0 |
|
- |
|
Patel Sanj K |
Chairman & CEO |
|
2021-02-10 |
4 |
OE |
$1.59 |
$2,544 |
D/D |
1,600 |
1,600 |
|
- |
|
Patel Sanj K |
Chairman & CEO |
|
2021-02-09 |
4 |
AS |
$23.08 |
$543,973 |
I/I |
(23,569) |
84,473 |
|
- |
|
Patel Sanj K |
Chairman & CEO |
|
2021-02-09 |
4 |
AS |
$23.04 |
$470,039 |
D/D |
(20,401) |
0 |
|
- |
|
Patel Sanj K |
Chairman & CEO |
|
2021-02-09 |
4 |
OE |
$1.59 |
$32,438 |
D/D |
20,401 |
20,401 |
|
- |
|
Patel Sanj K |
Chairman & CEO |
|
2021-02-08 |
4 |
AS |
$23.00 |
$104,144 |
I/I |
(4,528) |
108,042 |
|
- |
|
Patel Sanj K |
Chairman & CEO |
|
2021-02-08 |
4 |
AS |
$23.00 |
$113,252 |
D/D |
(4,924) |
0 |
|
- |
|
Patel Sanj K |
Chairman & CEO |
|
2021-02-08 |
4 |
OE |
$1.59 |
$7,829 |
D/D |
4,924 |
4,924 |
|
- |
|
Beetham Thomas W. |
EVP & Chief Legal Officer |
|
2021-02-03 |
4 |
AS |
$22.09 |
$54,717 |
D/D |
(2,477) |
297,523 |
|
- |
|
Beetham Thomas W. |
EVP & Chief Legal Officer |
|
2021-02-03 |
4 |
A |
$0.00 |
$0 |
D/D |
300,000 |
300,000 |
|
- |
|
Megna Michael R |
Chief Accounting Officer |
|
2020-12-31 |
4 |
A |
$15.02 |
$6,083 |
D/D |
405 |
2,183 |
|
- |
|
Rizvi Qasim |
Chief Commercial Officer |
|
2020-12-31 |
4 |
D |
$17.67 |
$38,185 |
D/D |
(2,161) |
5,176 |
|
- |
|
Rizvi Qasim |
Chief Commercial Officer |
|
2020-12-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,337 |
7,337 |
|
- |
|
241 Records found
|
|
Page 8 of 10 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|